• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Arcapta Neohaler (indacaterol maleate) Inhalation Powder 75 mcg

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012

 

Summary View

4 CONTRAINDICATIONS

ARCAPTA NEOHALER is contraindicated in patients with a history of hypersensitivity to indacaterol or to any of the ingredients. [see Warnings and Precautions (5.4)]

5 WARNINGS AND PRECAUTIONS

5.4 Immediate Hypersensitivity Reactions
  • Immediate hypersensitivity reactions may occur after administration of ARCAPTA NEOHALER. If signs suggesting allergic reactions (in particular, difficulties in rash) occur, ARCAPTA NEOHALER should be discontinued immediately and alternative therapy instituted.

6 ADVERSE REACTIONS

6.3 Postmarketing Experience
  • added ..... paradoxical bronchospasm
  • added ..... hypersentivity

MEDICATION GUIDE

  • information on hypersentivity reactions added